Aastrom Biosciences' Delegates to Present at Two Orthopaedic Meetings
17 March 2006 - 7:30AM
PR Newswire (US)
-- Technical and Clinical Presentations Scheduled at the Stem Cell
Summit and at the Combined Orthopaedic Research Society and
American Academy of Orthopaedic Surgeons Meetings -- ANN ARBOR,
Mich., March 16 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc.
(NASDAQ:ASTM) announced today that Company representatives are
scheduled to speak at the Stem Cell Summit, and at a symposia at
the combined meetings of the Orthopaedic Research Society and
American Academy of Orthopaedic Surgeons, which are being held at
separate locations in Chicago, IL next week. The presentations will
address the use of cell-based therapies in orthopaedic
applications, and in particular Aastrom's bone marrow-derived stem
cell-based Tissue Repair Cells (TRCs). (Logo:
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO ) On
Tuesday, March 21, 2006, the following Aastrom delegates will
present at the Stem Cell Summit: Janet M. Hock, B.D.S., Ph.D., Vice
President Global Research and Chief Scientific Officer; Jon Rowley,
Ph.D., Program Leader, Matrix Biology Group, and James Cour,
President and Chief Operating Officer. The Stem Cell Summit intends
to bring together scientists and clinicians to discuss the use of
adult stem cell-based therapies to treat orthopaedic patients. This
summit will be held at the Hotel Sofitel Chicago O'Hare. On
Wednesday, March 22, 2006, Dr. Janet Hock of Aastrom will introduce
and moderate a clinical symposia entitled "Use of Stem Cells in
Orthopaedic Applications" at the combined meetings of the
Orthopaedic Research Society and American Academy of Orthopaedic
Surgeons. Featured among the four-member panel of clinicians
scheduled to present is Matthew L. Jimenez, M.D., of the Illinois
Bone & Joint Institute. Dr. Jimenez is the Principal
Investigator at the lead site of Aastrom's U.S. Phase I/II
multi-center clinical trial evaluating the use of TRCs for the
treatment of non-union long bone fractures. During his
presentation, it is expected that Dr. Jimenez will review the
design of the multi-center clinical trial, and describe some of his
initial experiences in treating patients, who had failed other
standard of care treatments, with Aastrom's TRCs. These combined
meetings will be held at the Lakeside Center, McCormick Place
Convention Center. For more information about the Stem Cell Summit,
please visit RRY Publication's website at http://www.ryortho.com/.
For more information about the Orthopaedic Research Society, please
visit their website at http://www.ors.org/. For more information
about the American Association of Orthopaedic Surgeons, please
visit their website at http://www.aaos.org/. These meetings do not
provide for webcasting. About Aastrom Biosciences, Inc. Aastrom
Biosciences, Inc. (NASDAQ:ASTM) is developing products for the
repair or regeneration of multiple human tissues, based on its
proprietary Tissue Repair Cell (TRC) adult stem cell technology.
Aastrom's TRC products contain large numbers of stem, stromal and
progenitor cells that are produced from a small amount of bone
marrow cells originating from the patient. The AastromReplicell(R)
System, an industry-unique automated cell product manufacturing
platform, was developed for the production of standardized,
patient-specific TRC products. TRC products have been used safely
in humans as a substitute for bone marrow stem cells, and are
currently in clinical trials for bone grafting (long bone fractures
and spine fusion) and blood vessel regeneration (diabetic limb
ischemia) applications. The Company has recently reported positive
interim clinical trial results for its TRCs demonstrating both the
clinical safety and ability of TRCs to induce healthy new tissue
growth (long bone fractures and jaw bone reconstruction). For more
information, visit Aastrom's website at http://www.aastrom.com/.
This document contains forward-looking statements, including
without limitation, statements concerning product development
objectives, planned clinical trials, potential advantages of TRCs,
and potential product applications, which involve certain risks and
uncertainties. The forward-looking statements are also identified
through use of the words "intend," "plan," and other words of
similar meaning. Actual results may differ significantly from the
expectations contained in the forward-looking statements. Among the
factors that may result in differences are, potential product
development difficulties, clinical trial results, potential patient
accrual difficulties, the effects of competitive therapies,
regulatory approval requirements, the availability of financial and
other resources and the allocation of resources among different
potential uses. These and other significant factors are discussed
in greater detail in Aastrom's Annual Report on Form 10-K and other
filings with the Securities and Exchange Commission. CONTACTS: Kris
M. Maly Cameron Associates Investor Relations Department Kevin
McGrath Aastrom Biosciences, Inc. Phone: (212) 245-4577 Phone:
(734) 930-5777
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO
http://photoarchive.ap.org/ DATASOURCE: Aastrom Biosciences, Inc.
CONTACT: Kris M. Maly, Investor Relations Department of Aastrom
Biosciences, Inc., +1-734-930-5777; or Kevin McGrath of Cameron
Associates, +1-212-245-4577 Web site: http://www.aastrom.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024